TS-121

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 18:50, 21 November 2018 (removed Category:Drugs with unknown chemical structures; added Category:Drugs with undisclosed chemical structures using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

TS-121
Clinical data
Other namesTS-1211
Routes of
administration		By mouth

TS-121 is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[1][2] As of May 2017, it is in phase II clinical trials for this indication.[1][2]

See also

References

  1. ^ a b "TS 121 - AdisInsight".
  2. ^ a b "New Drug Pipeline - Taisho Pharmaceutical Holdings".

External links



Stub icon

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=TS-121&oldid=869996011"